MAAT INDEX

CLAIM #58973 · UnitedHealth Group Incorporated (UNH) · 2025Q4 earnings call · Jan 27, 2026 · due Dec 31, 2026

And so that puts us in a nice position to deliver a modest 2% earnings growth in 2026 for a business that we expect to return to the low double digit to high single digit low single digit to high excuse me. High single digit to low double digit, earnings growth.

Wayne DeVeydt · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Full-year 2026 earnings growth (segment/business earnings, as referenced) versus 2025

It came true if: Reported FY2026 earnings growth approximately 2% (within roughly 0-4% range)

Where: Company FY2026 earnings release / 10-K segment results, and management commentary on Q4 2026 earnings call

In context

w 2025 closed out on the pharmacy cost for us inside the health plan, I feel pretty good about the overall, you know, trend on balance. Between all the key drivers, things like specialty trend, brand utilization, etcetera. So it it gives me, you know, pretty good belief in our outlook and our positioning for 2026. And early in the year, I haven't seen anything to, suggest otherwise. For the question. Wayne DeVeydt: Fantastic, Bobby. And Lisa, thanks for the question. So maybe building on the the membership growth, I'll pick up, you know, where Patrick left off and some of his opening comments. Strong selling season. In 2026 combined with retention allowed us to backfill you know, continued high nineties, re from UHC. you know, about half, maybe more than half of the of the membership loss And so that puts us in a nice position to deliver a modest 2% earnings growth in 2026 for a business that we expect to return to the low double digit to high single digit low single digit to high excuse me. High single digit to low double digit, earnings growth. And if I unpack that, Lisa, to your question on what are we seeing in the market and why are we winning? Why did those 800 new clients choose OptumRx? Couple of points. You know, we our businesses are performing strongly. Each of our core businesses growing in the high single digits. And the reason we're winning threefold, affordability, transparency, and execution. From an affordability perspective, our clients have never needed us more than now. And good perspective activity there. We're committed to bringing affordability to those that we serve. For our clients, OptumRx generates more than a $100 billion in savings annually through negotiations with drug manufacturers and network pharmacies. And then for our members and patients, we deliver more than $1 billion savings annually through

Verify independently

SEC filings for UNH · Claim quote is verbatim from the 2025Q4 earnings call.